Stay updated with breaking news from Juanita yu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor The clinical trials of KRAS G12C inhibitors are expected to enroll patients in the second half of 2021. Jacobio is aiming for the in-house combination therapy of KRAS G12C and SHP2 inhibitors. Inhibitors targeting KRAS G12D and KRAS G12V mutations have lead compounds. News provided by Share this article Share this article BEIJING and SHANGHAI and BOSTON, May 2, 2021 /PRNewswire/ Jacobio Pharmaceuticals (1167.HK) has announced the U.S. Food and Drug Administration (FDA) has approved company s Investigational New Drug (IND) application to develop a KRAS G12C inhibitor. IND application to the National Medical Products Administration (NMPA) in China was accepted on March 17. It will be used to treat advanced solid tumors with the KRAS G12C mutation, including but not limited to non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors. Patient enr ....
Jacobio Pharma Announces CNY486 Million Revenue for 2020 Annual Results prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.